The safety of quinolones-A meta-analysis of pregnancy outcomes

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 143, Issue 2, 2009, Pages 75-78

  Bar Oz, Benjamin ^a,b   Moretti, Myla E ^a   Boskovic, Radinka ^a   O'Brien, Lisa ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Fluoroquinolones; Major malformations; Pregnancy outcome; Quinolones

Indexed keywords

CIPROFLOXACIN; ENOXACIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PEFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ARTICLE; BIRTH DEFECT; CASE CONTROL STUDY; CLINICAL EVALUATION; CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG EXPOSURE; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FIRST TRIMESTER PREGNANCY; HUMAN; INCIDENCE; LOW BIRTH WEIGHT; META ANALYSIS; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STILLBIRTH; SYSTEMATIC REVIEW; TERATOLOGY;

EID: 61849142240     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.12.007     Document Type: Article

References (27)

1. Hooper D.C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32 Suppl 1 (2001) S9-S15
2. Giamarellou H., Kolokythas E., Petrikkos G., Gazis J., Aravantinos D., and Sfikakis P. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 87 5A (1989) 49S-51S
3. Linseman D.A., Hampton L.A., and Branstetter D.G. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 28 1 (1995) 59-64
4. Yabe K., Satoh H., Ishii Y., et al. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent. Vet Pathol 41 6 (2004) 673-681
5. von Keutz E., Ruhl-Fehlert C., Drommer W., and Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol 78 7 (2004) 418-424
6. Danisovicova A., Brezina M., Belan S., et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey. Chemotherapy 40 3 (1994) 209-214
7. Ferech M., Coenen S., Malhotra-Kumar S., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 58 2 (2006) 423-427
8. Goossens H., Ferech M., Vander S.R., and Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 9459 (2005) 579-587
9. Linder J.A., Huang E.S., Steinman M.A., Gonzales R., and Stafford R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 118 3 (2005) 259-268
10. Berkovitch M., Pastuszak A., Gazarian M., Lewis M., and Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 84 4 (1994) 535-538
11. Czeizel A.E., Sorensen H.T., Rockenbauer M., and Olsen J. A population-based case-control teratologic study of nalidixic acid. Int J Gynaecol Obstet 73 3 (2001) 221-228
12. Dudas I., Puho E., and Czeizel A.E. Population-based case-control study of oxoline acid use during pregnancy for birth outcomes. Congenit Anom (Kyoto) 46 1 (2006) 39-42
13. Koren G. Use of the new quinolones during pregnancy. Can Fam Phys 42 (1996) 1097-1099
14. Larsen H., Nielsen G.L., Schonheyder H.C., Olesen C., and Sorensen H.T. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents 18 3 (2001) 259-262
15. Schaefer C., Amoura-Elefant E., Vial T., et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 69 2 (1996) 83-89
16. Wilton L.V., Pearce G.L., and Mann R.D. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 41 4 (1996) 277-284
17. Wogelius P., Norgaard M., Gislum M., Pedersen L., Schonheyder H.C., and Sorensen H.T. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents 26 4 (2005) 323-326
18. Loebstein R., Addis A., Ho E., et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 42 6 (1998) 1336-1339
19. Einarson T.R. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 19 3 (1997) 559-569
20. Downs S.H., and Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52 6 (1998) 377-384
21. Ferrero S., and Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270 2 (2004) 79-85
22. Bomford J.A.L., Ledger J.C., O'Keeffe B.J., and Reiter C. Ciprofloxacin use during pregnancy. Drugs 45 Suppl 3 (1993) 461-462
23. Koul P.A., Wani J.I., and Wahid A. Ciprofloxacin for multiresistant enteric fever in pregnancy. Lancet 346 8970 (1995) 307-308
24. Moskovitz D.N., Bodian C., Chapman M.L., et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 4 (2004) 656-661
25. Santolaria N., Vial T., Bellemin B., and Evreux I.C. Pregnancy outcome after first trimester fluoroquinolone exposure. Therapie 53 4 (1998) 179
26. Pastuszak A., Andreou R., Schick B., et al. New postmarketing surveillance data supports a lack of association between quinolone use in pregnancy and fetal and neonatal complications. Reprod Toxicol 9 6 (1995) 584
27. Camp B.W., Broman S.H., Nichols P.L., and Leff M. Maternal and neonatal risk factors for mental retardation: defining the 'at-risk' child. Early Hum Dev 50 2 (1998) 159-173